Relypsa - Top 15 Biotech VC Deals of 2010

Company: Relypsa
Based: Santa Clara, CA
Amount: $70M

Investors: OrbiMed Advisors, New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners

Scoop: Relypsa was founded by a group of ex-Ilypsa executives who got the rights to four preclinical programs they had been developing before Amgen bought the company for $420 million in 2009. Relypsa's lead compound is RLY5016, which the company's site describes as a "high capacity cation binder for the management of hyperkalemia in congestive heart failure (CHF) and chronic kidney disease (CKD) patients."

Relypsa's $70 million Series B provides the company with enough funding to see it through Phase III trials of RLY5016. Its total venture haul is more than $100 million.

Relypsa - Top 15 Biotech VC Deals of 2010
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.